Cost effectiveness of therapeutic interventions in ankylosing spondylitis: A critical and systematic review

PharmacoEconomics

Volumn 30, Issue 12, 2012, Pages 1145-1156

  Gaujoux Viala, Cécile ^a,b,c   Fautrel, Bruno ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Adalimumab; Ankylosing spondylitis; Cost effectiveness; Cost utility; Etanercept; Exercise therapy; Infliximab; Nonsteroidal anti inflammatories; Tumour necrosis factor alpha inhibitors

Indexed keywords

ADALIMUMAB; CELECOXIB; DICLOFENAC; ETANERCEPT; ETORICOXIB; INFLIXIMAB; NAPROXEN;

ANKYLOSING SPONDYLITIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; MATHEMATICAL MODEL; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; EXERCISE THERAPY; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869173398     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11596490-000000000-00000     Document Type: Review

References (32)

1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998 Jan; 41 (1): 58-67 (Pubitemid 28041923)
2. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. [letter]. Arthritis Rheum 2005 Dec; 52 (12): 4048-9; author reply 4049-50
3. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005 Oct; 64 (10): 1431-5 (Pubitemid 41623853)
4. Han C, Robinson Jr DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006 Nov; 33 (11): 2167-72 (Pubitemid 44749774)
5. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006 Apr; 65 (4): 442-52
6. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002 Apr 6; 359 (9313): 1187-93 (Pubitemid 34304258)
7. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003 Jun; 48 (6): 1667-75 (Pubitemid 36682375)
8. van der Heijde D, Landewé R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005 Jul; 52 (7): 1979-85 (Pubitemid 40994318)
9. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44 (8): 1876-86 (Pubitemid 32758236)
10. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 Dec; 21 (12): 2286-91
11. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 Dec; 21 (12): 2281-5
12. Van Tubergen A, Boonen A, Landewé R, et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2002 Oct 15; 47 (5): 459-67 (Pubitemid 35291365)
13. Bakker C, Hidding A, van der Linden S, et al. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis: A randomized controlled trial. J Rheumatol 1994 Feb; 21 (2): 264-8 (Pubitemid 24078838)
14. Jansen JP, Gaugris S, Choy EH, et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010 Apr 1; 28 (4): 323-44
15. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004 Sep; 43 (9): 1158-66 (Pubitemid 39232822)
16. Kobelt G, Andlin-Sobocki P, Maksymowych WP. The costeffectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006 Apr; 33 (4): 732-40
17. Kobelt G, Sobocki P, Sieper J, et al. Comparison of the costeffectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int J Technol Assess Health Care 2007; 23 (3): 368-75 (Pubitemid 46956880)
18. Kobelt G, Sobocki P, Mulero J, et al. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data. Scand J Rheumatol 2008 Jan-Feb; 37 (1): 62-71
19. Boonen A, van der Heijde D, Severens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006 Feb; 65 (2): 201-8 (Pubitemid 43131994)
20. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009 Jul; 36 (7): 1421-8
21. Fautrel B, Benhamou M, Breban M, et al. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Ann Rheum Dis 2010 Feb; 69 (2): 424-7
22. Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in theUK. Rheumatology (Oxford) 2007 Aug; 46 (8): 1338-44 (Pubitemid 47244511)
23. NeilsonAR, Sieper J,DeegM. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford) 2010 Nov; 49 (11): 2122-34
24. Botteman MF, Hay JW, Luo MP, et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007 Aug; 46 (8): 1320-8 (Pubitemid 47244509)
25. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108 (Pubitemid 127453463)
26. Oldroyd J, Schachna L, Buchbinder R, et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: A report from the Australian rheumatology association database. Int J Rheumatol 2009; 268569
27. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004 Nov; 42 (11): 1125-31 (Pubitemid 39472119)
28. National Institute for Health and Clinical Excellence. Incorporating health economics in guidelines and assessing resource impact. In: NICE. The guidelines manual. London: NICE, 2007: 49-55 [online]. Available from URL: Http:// www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter 8.pdf [Accessed 2012 Sep 11]
29. Boonen A, Maetzel A, Drummond M, et al. The OMERACT initiative: Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009 Sep; 36 (9): 2045-9
30. Eichler HG, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004 Sep-Oct; 7 (5): 518-28 (Pubitemid 39390832)
31. Nord E, Daniels N, Kamlet M. QALYs: Some challenges. Value Health 2009 Mar; 12 Suppl. 1: S10-5
32. Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22 (13): 857-76 (Pubitemid 39273956)